drugset / Trial / NCT02906059
Study of Irinotecan and AZD1775, a Selective Wee 1 Inhibitor, in RAS or BRAF Mutated, Second-line Metastatic Colorectal Cancer
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine whether combination therapy of irinotecan with AZD1775 is safe and effective in treating mutated metastatic colorectal cancer patients.
Timeline
- Start
- 2016-09
- Primary completion
- 2020-03-12
- Completion
- 2020-03-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Adavosertib | Small molecule | 125 mg | — |
| Subject | Adavosertib | Small molecule | 150 mg | — |
| Subject | Irinotecan | Small molecule | 180 mg/m2 | — |